1,089,119 Veradermics, Incorporated $MANE Shares Sold by Aberdeen Group plc

Aberdeen Group plc cut its position in Veradermics, Incorporated (NYSE:MANE – Free Report) by 99.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,523 shares of the company’s stock after selling 1,089,119 shares during the quarter. Aberdeen Group plc’s holdings in Veradermics were worth $912,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in MANE. Montanova Capital LLC bought a new stake in Veradermics in the second quarter valued at approximately $512,533,000. Bamco Inc. NY raised its stake in Veradermics by 284.8% in the 2nd quarter. Bamco Inc. NY now owns 229,581 shares of the company’s stock valued at $28,225,000 after acquiring an additional 169,913 shares during the period. Seven Fleet Capital Management LP bought a new stake in Veradermics in the 2nd quarter valued at $9,835,000. Wellington Management Group LLP acquired a new stake in Veradermics during the 2nd quarter valued at $8,425,000. Finally, Alps Advisors Inc. lifted its holdings in Veradermics by 31.2% during the 3rd quarter. Alps Advisors Inc. now owns 55,356 shares of the company’s stock valued at $6,711,000 after purchasing an additional 13,150 shares during the last quarter.

Analyst Ratings Changes

A number of research analysts recently commented on MANE shares. B. Riley Financial upped their price target on shares of Veradermics from $170.00 to $204.00 and gave the company a “buy” rating in a research note on Thursday, October 22nd. Needham & Company LLC upped their target price on Veradermics from $164.00 to $172.00 and gave the company a “buy” rating in a research report on Monday, October 19th. UBS Group set a $204.00 target price on Veradermics in a research note on Thursday, October 22nd. Citigroup boosted their price target on Veradermics from $160.00 to $175.00 and gave the company a “buy” rating in a research note on Tuesday, November 10th. Finally, Wall Street Zen raised Veradermics from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $174.57.

Read Our Latest Analysis on MANE

Veradermics Stock Performance

MANE opened at $119.39 on Friday. Veradermics, Incorporated has a 52-week low of $32.00 and a 52-week high of $156.63. The firm has a market cap of $5.04 billion and a P/E ratio of -49.75. The business’s fifty day moving average is $124.64 and its 200-day moving average is $99.06.

Veradermics (NYSE:MANE – Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.09. On average, research analysts predict that Veradermics, Incorporated will post -2.87 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Veradermics news, major shareholder Longitude Capital Partners V, sold 500,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 11th. The shares were sold at an average price of $150.38, for a total value of $75,190,000.00. Following the sale, the insider owned 1,803,474 shares in the company, valued at $271,206,420.12. This trade represents a 21.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link.

Veradermics Company Profile

(Free Report)

Veradermics is a clinical-stage biopharmaceutical company focused on developing treatments for hair loss. Its lead candidate, VDPHL01, is an investigational oral formulation of minoxidil being studied for androgenetic alopecia, commonly known as male- or female-pattern hair loss. The company has described the treatment as designed for once-daily use. VDPHL01 remains under clinical investigation and is not an approved treatment. Veradermics is led by founder and Chief Executive Officer Reid Waldman, a physician specializing in dermatology.

See Also

Institutional Ownership by Quarter for Veradermics (NYSE:MANE)

Receive News & Ratings for Veradermics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veradermics and related companies with MarketBeat.com's FREE daily email newsletter.